Author: Liu, Ching-Hsuan; Lu, Cheng-Hua; Wong, Shu Hui; Lin, Liang-Tzung
Title: Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects Cord-id: fy3lt8y7 Document date: 2021_2_5
ID: fy3lt8y7
Snippet: By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed cases and 1.6 million related deaths around the world. However, only a few drugs have been approved in certain areas and for use in conditional patients, and the vaccine candidates were only recently approved or authorized for emergency use without being fully implemented worldwide, suggesting that we are yet to reach effective control of the current outbreak as its uninhibited transmission continues precariously.
Document: By December 2020, the COVID-19 pandemic had caused more than 74 million confirmed cases and 1.6 million related deaths around the world. However, only a few drugs have been approved in certain areas and for use in conditional patients, and the vaccine candidates were only recently approved or authorized for emergency use without being fully implemented worldwide, suggesting that we are yet to reach effective control of the current outbreak as its uninhibited transmission continues precariously. Over the past few months, several therapeutic candidates have been proven ineffective in large clinical trials, while some other agents exhibited promising preliminary results. Meanwhile, the investigation of SARS-CoV-2-specific antivirals is underway. Despite still being preclinical, these agents could be beneficial for the long-term control of COVID-19 and deserve more research focus. In this article, we update the current status of therapeutic candidates that have been examined for COVID-19 management, including the virus-targeting inhibitors and host-targeting agents, with their antiviral efficacy in vitro, in vivo, and in clinical studies. Finally, we highlight the current challenges and future prospect of developing potent therapeutic agents against COVID-19.
Search related documents:
Co phrase search for related documents- accessory protein and active site bind: 1, 2
- accessory protein and acute respiratory disease: 1, 2, 3, 4, 5, 6
- accessory protein and acute respiratory distress syndrome: 1, 2, 3
- accessory protein and acute sars infection: 1
- accessory protein and lung adenocarcinoma: 1
- accessory protein and lung injury: 1, 2
- accessory protein and lung pathology: 1, 2
- accessory protein and lung tissue: 1, 2
- acidic environment and acute respiratory disease: 1
- acidic environment and acute respiratory distress syndrome: 1
- acidic environment and administration route: 1, 2
- acidic environment and low concentration: 1
- acidic environment and lung injury: 1
- acidic environment and lung tissue: 1
- acting antiviral and acute respiratory disease: 1, 2, 3, 4, 5
- acting antiviral and acute respiratory distress syndrome: 1, 2, 3, 4
- acting antiviral and acute sars infection: 1, 2, 3
- acting antiviral and lung injury: 1
- acting antiviral and lung liver: 1
Co phrase search for related documents, hyperlinks ordered by date